If they don't get it the RS will probably still be rejected and Cox will most likely be fired (followed by an austerity program... and because Atryn looks like such a blockbuster drug they don't really need their other stuff).
More upside then downside short term.
The nightmare sequence is the RS gets approved, followed by the massive dilution (with no partnership), and Cox staying on. But I consider that rather unlikely.
News 
Market Data 
Discover 
